On the stock market since 2022, it operates in the world of health and science. It has 240 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
Average growth of 116% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
Over the last 3 years, sales grew about 105% a year on average.
Sales run at $87.1M a year. A small number, but proof the product has real buyers.
There is $62.7M in the vault; even if every debt were paid off, $60.8M would remain.
A loss of $26.0M against $87.1M in annual sales.
This stock swings about 2.7 times as much as the market average. Big rallies — and big drops — can both happen fast.
At the current pace of spending, the cash lasts about 2.4 years. After that, the company needs to find new money.
On our five-subject report card, DLHTF sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: DLHTF is a high-risk stock — not yet profitable, and its future rides on its product catching on.